Pituitary‐related immune adverse events induced by programmed death Protein‐1 inhibitors differ clinically from hypophysitis
Authors' conclusion
In our study, pituitary immune-related adverse reactions induced by PD-1 inhibitors mainly manifested isolated ACTH deficiency rather than hypophysitis.
Study context
- Population
- Chinese patients with pituitary immune-related adverse events induced by PD-1 inhibitors, plus published cases47 articles reviewed
- Participants
- 14 vs 94
- Exposure
- Own cohort vs previously published cases
- Ourn = 14
- Previous literaturesn = 94
- Outcome
- Isolated ACTH deficiency (IAD) among pituitary irAEs induced by PD-1 inhibitors
Methodological detailssingle cohort, literature review (PubMed, 1950–2023)
- Single cohort
- Literature review (PubMed, 1950–2023)
Main finding
As reported in the abstract
Our cohort
85.71%
12 of 14
- Isolated ACTH deficiency (IAD) in previous studies reviewed (78/94)
- 82.98%
Observational data: associations, not effects.
Further findings
Central adrenocortical insufficiency
| Outcome | Our | Previous literatures |
|---|---|---|
| >1 hypothalamic-pituitary axis injury | 14.29% | — not stated in the abstract |
— not stated in the abstract
Pituitary imaging
- Our cohort: no pituitary enlargement on MRI
- 14/14
- Previous literatures: no abnormality of the pituitary gland
- 78.33% (47/60)
Typical hypophysitis features
- No pituitary enlargement, headache, visual field defects or multiple pituitary function impairments in our cohort and previous literatures
Original publication
Pituitary‐related immune adverse events induced by programmed death Protein‐1 inhibitors differ clinically from hypophysitis. Clin Endocrinol (Oxf). Published 16 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →